| 000 | 01217 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250517070104.0 | ||
| 264 | 0 | _c20160929 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1744-8328 | ||
| 024 | 7 |
_a10.1586/14737140.2016.1131614 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMorley, N J | |
| 245 | 0 | 0 |
_aInotuzumab ozogamicin in the management of acute lymphoblastic leukaemia. _h[electronic resource] |
| 260 |
_bExpert review of anticancer therapy _c2016 |
||
| 300 |
_a159-64 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInotuzumab Ozogamicin |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRecurrence |
| 700 | 1 | _aMarks, D I | |
| 773 | 0 |
_tExpert review of anticancer therapy _gvol. 16 _gno. 2 _gp. 159-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1586/14737140.2016.1131614 _zAvailable from publisher's website |
| 999 |
_c25529991 _d25529991 |
||